Key terms
About DCTH
Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in Queensbury, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest DCTH news
Mar 27
6:06am ET
Delcath Systems price target raised to $20 from $18 at H.C. Wainwright
Mar 19
8:12am ET
Delcath Systems Welcomes New COO Martha S. Rook
Mar 18
5:21pm ET
Delcath Systems names Martha Rook as COO
Mar 15
8:21am ET
Delcath Systems to sell 876,627 shares at $3.72 in private placement
Feb 14
4:12pm ET
Delcath Systems Executives Announce Retirement Plans
Feb 02
7:31am ET
Analysts Are Bullish on Top Healthcare Stocks: BioNano Genomics (BNGO), Legend Biotech (LEGN)
Jan 31
8:07am ET
Delcath Systems announces CMS established product-specific J-code for HEPZATO
Jan 07
5:27am ET
BTIG Sticks to Its Buy Rating for Delcath Systems (DCTH)
Jan 02
9:09am ET
BTIG Remains a Buy on Delcath Systems (DCTH)
Dec 31
5:12am ET
BTIG Sticks to Their Buy Rating for Delcath Systems (DCTH)
No recent press releases are available for DCTH
DCTH Financials
Key terms
Ad Feedback
DCTH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
DCTH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range